Abeona Therapeutics Receives Upgrade to Hold by StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) has been upgraded by equity research analysts at StockNews.com from a "sell" rating to a "hold" rating. This upgrade was communicated to investors in a note released on a recent Friday.

In addition to StockNews.com's upgrade, several other research firms have provided their insights on Abeona Therapeutics. Cantor Fitzgerald reaffirmed an "overweight" rating, setting a price target of $18.00 for the company's shares in a research note dated Tuesday, October 29. Meanwhile, HC Wainwright maintained a "buy" rating and established a $15.00 target price in a report released on Monday, November 25.

Abeona Therapeutics Stock Performance

On Friday, the shares of Abeona Therapeutics opened at $5.93. The company has strong liquidity, indicated by a current ratio and quick ratio of 6.12. Its debt-to-equity ratio stands at 0.31. Abeona Therapeutics has a market capitalization of approximately $257.78 million and a price-to-earnings ratio of -2.20, with a beta of 1.43. Over the past year, the stock has seen a low of $3.05 and a high of $9.01. The 50-day moving average is $5.66, and the 200-day moving average is $5.77.

Institutional Investor Activity

Recent trends show that hedge funds and other institutional investors have been active in adjusting their stakes in Abeona Therapeutics. For example, Jane Street Group LLC acquired a new position in the company in the third quarter valued at $84,000. Similarly, Charles Schwab Investment Management purchased shares worth $151,000 in the same quarter. XTX Topco Ltd also bought into the company, investing $160,000 during the third quarter. Meanwhile, Trexquant Investment LP made a substantial investment of $382,000 in the fourth quarter. Notably, JPMorgan Chase & Co. increased its holdings by 74.2% during the third quarter, owning 67,138 shares valued at $424,000 after purchasing an additional 28,606 shares. Currently, institutional investors hold about 80.56% of Abeona Therapeutics' stock.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to developing and delivering gene therapy treatments aimed at addressing severe and life-threatening rare diseases. The company's leading projects include EB-101, which focuses on gene-corrected skin grafts for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, an AAV-based gene therapy for Sanfilippo syndrome type A; and ABO-101, which targets Sanfilippo syndrome type B through an adeno-associated virus (AAV) based approach.

Further Information

• Explore alternative stocks with potential beyond Abeona Therapeutics
• Guide on effectively using stock screeners for investing
• Momentum on Upstart's upward trend: Is it time to invest?
• Understanding the composition of the Dow Jones Industrial Average (DJIA)
• Latest news on Archer Aviation's investment and future plans
• Maximizing the benefits of MarketBeat's earnings screener
• Insights on Buffett's additional purchases in Occidental Petroleum

To stay updated on news and analyst ratings for Abeona Therapeutics and similar companies, consider subscribing to a summary newsletter.

Abeona, Stocks, Upgrade